Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib

References

• KreutzfeldtJ, RozeboomB, DeyN, DeP. The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. Am J Cancer Res. 2020;10:1045–1067.32368385
   PubMed Web of Science ®Google Scholar
• CescaMG, VianL, Cristóvão-FerreiraS, PondéN, de AzambujaE. HER2-positive advanced breast cancer treatment in 2020. Cancer Treat Rev. 2020;88. doi:10.1016/j.ctrv.2020.102033
   Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu Oncogene.Science. 1987. Jan 9;235(4785):177-82.doi:10.1126/science.3798106
   Google Scholar
• YaoM, FuP. Advances in anti-HER2 therapy in metastatic breast cancer. Chin Clin Oncol. 2018;7:1–9. doi:10.21037/cco.2018.05.0429156890
   PubMed Web of Science ®Google Scholar
• SwainSM, Baselga J, Kim, SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:519–530. doi:10.1016/S1470-2045(19)30863-032171426
   PubMed Web of Science ®Google Scholar
• ClynesRA, TowersTL, PrestaLG, RavetchJV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443–446. doi:10.1038/7470410742152
   PubMed Web of Science ®Google Scholar
• SlamonDJ, Leyland-Jones B, Shaket S, et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792. doi:10.1056/NEJM20010315344110111248153
   PubMed Web of Science ®Google Scholar
• Luque-CabalM, García-TeijidoP, Fernández-PérezY, Sánchez-LorenzoL, Palacio-VázquezI. Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome It. Clin Med Insights Oncol. 2016;10:21–30. doi:10.4137/CMO.S3453727042153
   PubMed Web of Science ®Google Scholar
• ChumsriS, SperindeJ, LiuH, et al. High p95HER2/HER2 ratio associated with poor outcome in trastuzumab-treated HER2-positive metastatic breast cancer ncctg N0337 and NCCTG 98- 32-52(Alliance). Clin Cancer Res. 2018;24:3053–3058. doi:10.1158/1078-0432.CCR-17-186429530935
   PubMed Web of Science ®Google Scholar
• ScaltritiM, Chandarlapaty S, Prudkin L, et al. Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res. 2010;16:2688–2695. doi:10.1158/1078-0432.CCR-09-340720406840
   PubMed Web of Science ®Google Scholar
• ZhuangG, Brantley-Sieders DM, Vaught D, et al. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res. 2010;70:299–308. doi:10.1158/0008-5472.CAN-09-184520028874
   PubMed Web of Science ®Google Scholar
• KonecnyGE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006;66:1630–1639. doi:10.1158/0008-5472.CAN-05-118216452222
   PubMed Web of Science ®Google Scholar
• BendellJC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97:2972–2977. doi:10.1002/cncr.1143612784331
   PubMed Web of Science ®Google Scholar
• BredinP, WalsheJM, DenduluriN. Systemic therapy for metastatic HER2-positive breast cancer. Semin Oncol. 2020. doi:10.1053/j.seminoncol.2020.07.008
   Web of Science ®Google Scholar
• LeoneJP, LinNU. Systemic therapy of central nervous system metastases of breast cancer. Curr Oncol Rep. 2019;21.30806814
   PubMed Web of Science ®Google Scholar
• Terrell-HallTB, NounouMI, El-AmrawyF, GriffithJIG, LockmanPR. Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer. Oncotarget. 2017;8:83734–83744. doi:10.18632/oncotarget.1963429137378
   PubMedGoogle Scholar
• StemmlerHJ, Schmitt, M, Willems, A, et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs. 2007;18:23–28. doi:10.1097/01.cad.0000236313.50833.ee17159499
   PubMed Web of Science ®Google Scholar
• LinNU, Kumthekar P, Sahebjam S, et al. Abstract P1-18-03: pertuzumab (P) plus high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression after radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC): primary efficacy analysis results from the phase II PATRICIA study. Cancer Res. 2020. 80 P1-18-03-P1-18–03 (American Association for Cancer Research (AACR).
   Web of Science ®Google Scholar
• MirO, RopertS, AlexandreJ, LemareF, GoldwasserF. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol. 2008;19:1978–1980. doi:10.1093/annonc/mdn65418845838
   PubMed Web of Science ®Google Scholar
• KordbachehT, LawWY, SmithIE. Sanctuary site leptomeningeal metastases in HER-2 positive breast cancer: a review in the era of trastuzumab. Breast. 2016;26:54–58. doi:10.1016/j.breast.2015.11.00527017242
   PubMed Web of Science ®Google Scholar
• BonneauC, Paintaud G, Trédan O, et al. Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. Eur J Cancer. 2018;95:75–84. doi:10.1016/j.ejca.2018.02.03229635147
   PubMed Web of Science ®Google Scholar
• ArvoldND,Lee EQ, Mehta MP, et al. Updates in the management of brain metastases. Neuro Oncol. 2016;18:1043–1065. doi:10.1093/neuonc/now12727382120
   PubMed Web of Science ®Google Scholar
• RamakrishnaN, Temin S ,Chandarlapaty S, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32:2100–2108. doi:10.1200/JCO.2013.54.095524799487
   PubMed Web of Science ®Google Scholar
• BrownPD, Ahluwalia MS, Khan OH, Asher AL, Wefel JS, Gondi V, et al. Whole-brain radiotherapy for brain metastases: evolution or revolution?J Clin Oncol. 2018;36:483–491. doi:10.1200/JCO.2017.75.958929272161
   PubMed Web of Science ®Google Scholar
• ChoE, Rubinstein L, Stevenson P, et al. The use of stereotactic radiosurgery for brain metastases from breast cancer: who benefits most?Breast Cancer Res Treat. 2015;149:743–749. doi:10.1007/s10549-014-3242-x25638395
   PubMed Web of Science ®Google Scholar
• VickersEP. A Beginner’s Guide to Targeted Cancer Treatments. Wiley Blackwell; 2018.
   Google Scholar
• HartmannJ, HaapM, KoppH-G, LippH-P. Tyrosine kinase inhibitors – a review on pharmacology, metabolism and side effects. Curr Drug Metab. 2009;10:470–481. doi:10.2174/13892000978889797519689244
   PubMed Web of Science ®Google Scholar
• HarbeckN, Huang CS, Hurvitz S, et al. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet Oncol. 2016;17:357–366. doi:10.1016/S1470-2045(15)00540-926822398
   PubMed Web of Science ®Google Scholar
• CortésJ, Dieras V, RoetJ, et al. Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 tr. Lancet Oncol. 2015;16:1700–1710. doi:10.1016/S1470-2045(15)00373-326596672
   PubMed Web of Science ®Google Scholar
• KimTM, Lee KW, Oh DY, et al. Phase 1 studies of poziotinib, an irreversible pan-her tyrosine kinase inhibitor in patients with advanced solid tumors. Cancer Res Treat. 2018;50:835–842. doi:10.4143/crt.2017.30328859471
   PubMed Web of Science ®Google Scholar
• ParkYH, Lee, KH, Sohn JH, et al. A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial. Int J Cancer. 2018;143:3240–3247. doi:10.1002/ijc.3165129978467
   PubMed Web of Science ®Google Scholar
• MaF, Li Q, ChenetS, et al. Phase I study and biomarker analysis of pyrotinib, a novel irreversible Pan-ERBB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer. J Clin Oncol. 2017;35:3105–3112. doi:10.1200/JCO.2016.69.617928498781
   PubMed Web of Science ®Google Scholar
• BrufskyA, Zulfiqar M, Peguero J, et al. A phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer heavily pre-treated with HER2-targeted therapy. San Antonio Breast Cancer Symp. 2020. PD1–PD07.
   Google Scholar
• GiordanoSH, Temin S, Chandarlapaty S, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32:2078–2099. doi:10.1200/JCO.2013.54.094824799465
   PubMed Web of Science ®Google Scholar
• JiangH, RugoHS. Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options. Ther Adv Med Oncol. 2015;7:321–339. doi:10.1177/175883401559938926557900
   PubMed Web of Science ®Google Scholar
• XuhongJ-C, QiX-W, ZhangY, JiangJ. Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. Am J Cancer Res. 2019;9:2103–2119.31720077
   PubMed Web of Science ®Google Scholar
• BachelotT, Ciruelos E, Schneeweiss A, et al. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann Oncol. 2019;30:766–773. doi:10.1093/annonc/mdz06130796821
   PubMed Web of Science ®Google Scholar
• SwainSM, Baselga J, Miles D, et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. 2014;25:1116–1121. doi:10.1093/annonc/mdu13324685829
   PubMed Web of Science ®Google Scholar
• VermaS,Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–1791. doi:10.1056/NEJMoa120912423020162
   PubMed Web of Science ®Google Scholar
• KropIE, Kim SB, González-Martín A, et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18:743–754. doi:10.1016/S1470-2045(17)30313-328526538
   PubMed Web of Science ®Google Scholar
• PerezEA, Barrios CH, Eiermann W, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study. J Clin Oncol. 2017;35:141–148. doi:10.1200/JCO.2016.67.488728056202
   PubMed Web of Science ®Google Scholar
• MontemurroF,Delaloge S, Barrios CH, et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Ann Oncol. 2020;31:1350–1358. doi:10.1016/j.annonc.2020.06.02032634611
   PubMed Web of Science ®Google Scholar
• BlackwellKL, Pegram MD, Tan-Chiu E, et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol. 2009;20:1026–1031. doi:10.1093/annonc/mdn75919179558
   PubMed Web of Science ®Google Scholar
• BlackwellKL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol. 2012;30:2585–2592. doi:10.1200/JCO.2011.35.672522689807
   PubMed Web of Science ®Google Scholar
• GiordanoSH, Temin S, Chandarlapaty S, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2–positive breast cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36:2736–2740. doi:10.1200/JCO.2018.79.269729939838
   PubMed Web of Science ®Google Scholar
• GuanZ, Xu B, DeSilvio ML, et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2–overexpressing metastatic breast cancer. J Clin Oncol. 2013;31:1947–1953. doi:10.1200/JCO.2011.40.524123509322
   PubMed Web of Science ®Google Scholar
• GelmonKA, Boyle FM, Kaufman B, et al. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31. J Clin Oncol. 2015;33:1574–1583. doi:10.1200/JCO.2014.56.959025779558
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–2743. doi:10.1056/NEJMoa06432017192538
   PubMed Web of Science ®Google Scholar
• LousbergL, CollignonJ, JerusalemG. Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies. Ther Adv Med Oncol. 2016;8:429–449. doi:10.1177/175883401666507727800032
   PubMed Web of Science ®Google Scholar
• JohnstonS, Pippen Jr J ,PivotetX, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor - Positive metastatic breast cancer. J Clin Oncol. 2009;27:5538–5546. doi:10.1200/JCO.2009.23.373419786658
   PubMed Web of Science ®Google Scholar
• JohnstonSRD, Hegg R, Im SA, et al. Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor–positive metastatic breast. J Clin Oncol. 2020. doi:10.1200/jco.20.01894
   Web of Science ®Google Scholar
• RimawiM, Ferrero JM, Haba-Rodriguez, J, et al. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol. 2018;36:2826–2835. doi:10.1200/JCO.2017.76.7863.30106636
   PubMed Web of Science ®Google Scholar
• ArpinoG, Haba-Rodriguez J, Ferrero JM, et al. Final analysis of PERTAIN: a randomised, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of first-line pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in patients with HER2-positive and hormone. San Antonio Breast Cancer Symp. 2020. PD02–PD3.
   Google Scholar
• Baez-VallecilloL, Raghavendra AS, Hesset KR, et al. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). Breast Cancer Res Treat. 2019;176:227–234. doi:10.1007/s10549-018-05081-z30977027
   PubMed Web of Science ®Google Scholar
• GrilB, Palmieri D, Bronder JL, et  al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst. 2008;100:1092–1103. doi:10.1093/jnci/djn21618664652
   PubMed Web of Science ®Google Scholar
• SaleemA, Searle GE, Kenny LM, et al. Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer. EJNMMI Res. 2015;5. doi:10.1186/s13550-015-0103-5
   Web of Science ®Google Scholar
• LinNU, Diéras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15:1452–1459. doi:10.1158/1078-0432.CCR-08-108019228746
   PubMed Web of Science ®Google Scholar
• LinNU,  Eierman W, GreiletR, et al. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol. 2011;105:613–620. doi:10.1007/s11060-011-0629-y21706359
   PubMed Web of Science ®Google Scholar
• BachelotT, Romieu G, Campone MD, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14:64–71. doi:10.1016/S1470-2045(12)70432-123122784
   PubMed Web of Science ®Google Scholar
• PivotX, Manikhas A, Żurawski B, et al. CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015;33:1564–1573. doi:10.1200/JCO.2014.57.179425605838
   PubMed Web of Science ®Google Scholar
• LarionovAA. Current therapies for human epidermal growth factor receptor 2-positive metastatic breast cancer patients. Front Oncol. 2018;8. doi:10.3389/fonc.2018.00089
   Web of Science ®Google Scholar
• RabindranSK, Discafani CM, Rosfjord EC, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 2004;64:3958–3965. doi:10.1158/0008-5472.CAN-03-286815173008
   PubMed Web of Science ®Google Scholar
• CanoniciA, Gijsen M, Mullooly M, et al. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 2013;4:1592–1605. doi:10.18632/oncotarget.114824009064
   PubMed Web of Science ®Google Scholar
• ItoY, Suenaga M, Hatake K,et al. Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a phase 1 dose-escalation study. Jpn J Clin Oncol. 2012;42:278–286. doi:10.1093/jjco/hys01222371427
   PubMed Web of Science ®Google Scholar
• BursteinHJ,Sun Y, Dirixet LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010;28:1301–1307. doi:10.1200/JCO.2009.25.870720142587
   PubMed Web of Science ®Google Scholar
• MartinM, Bonneterre J, Geyer CE, et al. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer. 2013;49:3763–3772. doi:10.1016/j.ejca.2013.07.14223953056
   PubMed Web of Science ®Google Scholar
• BlackwellKL, Zaman K, Qin S, et al. Neratinib in combination with trastuzumab for the treatment of patients with advanced HER2-positive breast cancer: a Phase I/II study. Clin Breast Cancer. 2019;19:97–104.e4. doi:10.1016/j.clbc.2018.12.01130655172
   PubMed Web of Science ®Google Scholar
• AbrahamJ, Montero AJ, Jankowitz RC, et al. Safety and efficacy of T-DM1 plus neratinib in patients with metastatic HER2-positive breast cancer: NSABP Foundation Trial FB-10. J Clin Oncol. 2019;37:2601–2609. doi:10.1200/JCO.19.0085831442103
   PubMed Web of Science ®Google Scholar
• SauraC, Garcia-Saenz JA , Xu B,  et al. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2014;32:3626–3634. doi:10.1200/JCO.2014.56.380925287822
   PubMed Web of Science ®Google Scholar
• SauraC, OliveiraM, FengY-H, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA Trial. J. Clin. Oncol. 2020;38:3138–3149. doi:10.1200/JCO.20.0014732678716
   PubMed Web of Science ®Google Scholar
• OliveiraM, GarrigósL, AssafJD, Escrivá-de-romaníS, SauraC. Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer. Expert Rev Anticancer Ther. 2020;00:1–11.
   Google Scholar
• MoyB, Oliveira M, Saura C, et al. Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and ≥ 2 prior HER2-directed regimens. San Antonio Breast Cancer Symp. 2020. PS9-PS02.
   Google Scholar
• BarcenasCH, HurvitzSA, Di PalmaJA, et al. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Ann.Oncol. 2020;31:1223–1230. doi:10.1016/j.annonc.2020.05.01232464281
   PubMed Web of Science ®Google Scholar
• AwadaA, ColomerR, InoueK, et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer the NEfERT-T randomized clinical trial. JAMA Oncol. 2016;2:1557–1564. doi:10.1001/jamaoncol.2016.023727078022
   PubMed Web of Science ®Google Scholar
• FreedmanRA, GelmanRS, AndersCK, et al. TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol. 2019;37:1081–1089. doi:10.1200/JCO.18.0151130860945
   PubMed Web of Science ®Google Scholar
• MartinM, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1688–1700.29146401
   PubMed Web of Science ®Google Scholar
• KulukianA, LeeP, TaylorJ, et al. Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models. Mol Cancer Ther. 2020;19:976–987. doi:10.1158/1535-7163.MCT-19-087332241871
   PubMed Web of Science ®Google Scholar
• PhenegerTBouhana A, Anderson D, et al. Abstract #1795: in Vitro and in vivo activity of ARRY-380: a potent, small molecule inhibitor of ErbB2. Cancer Res. 2009;69.
   Google Scholar
• DinkelVAnderson D, Winski S, et al. Abstract 852: ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+ xenograft models in mice. Cancer Res. 2012;72:852.
   Web of Science ®Google Scholar
• MoulderSL, BorgesVF, BaetzT, et al. Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2 +-Advanced Solid Tumors, with an Expansion Cohort in HER2 + Metastatic Breast Cancer (MBC). Clin Cancer Res. 2017;23:3529–3536. doi:10.1158/1078-0432.CCR-16-149628053022
   PubMed Web of Science ®Google Scholar
• MurthyR, BorgesVF, ConlinA, et al. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19:880–888. doi:10.1016/S1470-2045(18)30256-029804905
   PubMed Web of Science ®Google Scholar
• Von MinckwitzG, SchwedlerK, SchmidtM, et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer. 2011;47:2273–2281. doi:10.1016/j.ejca.2011.06.02121741829
   PubMed Web of Science ®Google Scholar
• MurthyRK, LoiS, OkinesA, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382:597–609. doi:10.1056/NEJMoa191460931825569
   PubMed Web of Science ®Google Scholar
• BartschR, WenzelC, AltorjaiG, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol. 2007;25:3853–3858. doi:10.1200/JCO.2007.11.977617679724
   PubMed Web of Science ®Google Scholar
• LeeA. Tucatinib: first Approval. Drugs. 2020;80:1033–1038. doi:10.1007/s40265-020-01340-w32548668
   PubMed Web of Science ®Google Scholar
• MuellerV, PaplomataE, HamiltonEP, et al. 275O Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM). Ann Oncol. 2020;31:S349–S350. doi:10.1016/j.annonc.2020.08.377
   Web of Science ®Google Scholar
• WuQ, Liao W, Zhang M, Huang J, Zhang P, Li Q. Cost-effectiveness of tucatinib in human epidermal growth factor receptor 2–positive metastatic breast cancer from the US and Chinese perspectives. Front Oncol. 2020;10:1–11. doi:10.3389/fonc.2020.0000132076595
   PubMed Web of Science ®Google Scholar
• KulukianA, Taylor J, Olson D, et al. Abstract P1-18-09: tucatinib, a HER2-selective tyrosine kinase inhibitor, increases the anti-tumor activity of trastuzumab antibody-drug conjugates in preclinical models of HER2+ breast cancer. Cancer Res. 2020;80. P1-18-09-P1-18–09 (American Association for Cancer Research (AACR).
   Web of Science ®Google Scholar
• BorgesVF, FerrarioC, AucoinN, et al. Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2 -positive metastatic breast cancer. JAMA Oncol. 2018;4:1214–1220. doi:10.1001/jamaoncol.2018.181229955792
   PubMed Web of Science ®Google Scholar
• ShagisultanovaE, ChalasaniP, Brown-GlabermanUA, et al. Tucatinib, palbociclib, and letrozole in HR+/HER2+ metastatic breast cancer: report of phase IB safety cohort. J Clin Oncol. 2019;37:1029. doi:10.1200/JCO.2019.37.15_suppl.1029
   Web of Science ®Google Scholar
• LinNU, BorgesV, AndersC, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38:2610–2619. doi:10.1200/JCO.20.0077532468955
   PubMed Web of Science ®Google Scholar
• WardleyA, Mueller V, Paplomata E, et al. Impact of tucatinib on health-related quality of life in patients with HER2+ metastatic breast cancer with stable and active brain metastases. San Antonio Breast Cancer Symp. 2020. PD04–PD13.
   Google Scholar
• OlsonEM, Abdel-RasoulM, MalyJ, et al. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Ann Oncol. 2013;24:1526–1533. doi:10.1093/annonc/mdt03623463626
   PubMed Web of Science ®Google Scholar
• von MinckwitzG, HuangC-S, ManoMS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617–628. doi:10.1056/NEJMoa181401730516102
   PubMed Web of Science ®Google Scholar
• LoiblS, HuangC-S, ManoMS, et al. 96O Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: subgroup analysis from KATHERINE. Ann Oncol. 2020;31:S48. doi:10.1016/j.annonc.2020.03.036
   Web of Science ®Google Scholar
• LiR, Sant S, Brown E, et al. Tucatinib favourably modulates the immune microenvironment and synergises with anti-PD1 therapy in a trastuzumab resistant HER2+ murine model. San Antonio Breast Cancer Symp. 2020.
   Google Scholar
• ConlonNTKooijman JJ, van Gerwen SJC, et al. Comparative analysis of anti-proliferative effects and gene profiling of lapatinib, neratinib, and tucatinib. San Antonio Breast Cancer Symp. 2020. PS10-PS06.
   Google Scholar
• XuX, De AngelisC, BurkeKA, et al. HER2 reactivation through acquisition of the HER2 L755S mutation as a mechanism of acquired resistance to HER2-targeted therapy in HER2 + breast cancer. Clin Cancer Res. 2017;23:5123–5134. doi:10.1158/1078-0432.CCR-16-219128487443
   PubMed Web of Science ®Google Scholar
• VeeraraghavanJ, Mistry R, Nanda S, et al. HER2 L755S mutation is acquired upon resistance to lapatinib and neratinib and confers cross-resistance to tucatinib and trastuzumab in HER2-positive breast cancer cell models. San Antonio Breast Cancer Symp. 2020. PD3-PD09.
   Google Scholar
• Metzger FilhoO, Leone JP, Liet T, etal. Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases. Ann Oncol. 2020;31:1231–1239. doi:10.1016/j.annonc.2020.05.01432461105
   PubMed Web of Science ®Google Scholar
• Escrivá-de-romaníS, ArumíM, BelletM, SauraC. HER2-positive breast cancer: current and new therapeutic strategies. Breast. 2018;39:80–88. doi:10.1016/j.breast.2018.03.00629631097
   PubMed Web of Science ®Google Scholar
• KunteS, AbrahamJ, MonteroAJ. Novel HER2–targeted therapies for HER2–positive metastatic breast cancer. Cancer. 2020;126:4278–4288. doi:10.1002/cncr.3310232721042
   PubMed Web of Science ®Google Scholar
• MaF, Ouyang Q, Li W, et al. Pyrotinib or lapatinib combined with capecitabine in HER2–positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase II study. J Clin Oncol. 2019;37:2610–2619. doi:10.1200/JCO.19.0010831430226
   PubMed Web of Science ®Google Scholar
• XuBYan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:351–360. doi:10.1016/S1470-2045(20)30702-633581774
   PubMed Web of Science ®Google Scholar
• ModiS,Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610–621. doi:10.1056/NEJMoa191451031825192
   PubMed Web of Science ®Google Scholar
• ModiS, Saura C, Yamashita T, et al. Updated results from DESTINY-Breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer. San Antonio Breast Cancer Symp. 2020. PD3-PD06.
   Google Scholar
• JerusalemG, Park YH, Yamashita T, et al. CNS metastases in HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan: DESTINY-Breast01 subgroup analyses. ESMO Breast Cancer Virtual Meeting. 2020;1380.
   Google Scholar
• TamuraK, Tsurutani J, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019;20:816–826. doi:10.1016/S1470-2045(19)30097-X31047803
   PubMed Web of Science ®Google Scholar